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Leishmania major parasites lacking the GDP-mannose transporter, termed lpg2 parasites, fail to induce
disease in mice but persist long-term. We previously found that lpg2 organisms protect BALB/c mice from
virulent L. major challenge. In contrast, we report here that lpg2 parasites induce protective immunity in
C57BL/6 mice only when administered with CpG-containing oligodeoxynucleotides, indicating that parasite
persistence alone is not sufficient to maintain protective immunity to L. major.
Following infection with Leishmania major, mice that have
achieved a clinical cure harbor persistent parasites and main-
tain a life-long immunity to reinfection (1, 3, 11). Persistent
live parasites are required for the maintenance and/or renewal
of anti-Leishmania effector memory cells that produce gamma
interferon (IFN-), mediate a delayed-type hypersensitivity
(DTH) response, and induce rapid protection against virulent
challenge (13). Although they are required for durable immu-
nity, persistent virulent parasites may cause disease recrudes-
cence in immunocompromised individuals. Therefore, the gen-
eration of live, attenuated parasites that persist without
causing disease would be a reasonable approach to generating
a vaccine for leishmaniasis. BALB/c mice are extremely sus-
ceptible to L. major in part due to the development of a Th2
response (8). To determine if lpg2 parasites can protect mice
that do not develop a dominant Th2 response, we tested the
protective potential of lpg2 mutants in C57BL/6 mice.
C57BL/6 mice develop a Th1 response following L. major
infection and heal over 2 to 3 months. Following resolution of
a primary infection, these mice exhibit substantial protective
immunity to reinfection (7). In this report we show that al-
though lpg2 parasites are maintained long-term in C57BL/6
mice, they provide minimal protection to virulent challenge,
although when they were delivered with CpG oligodeoxynucle-
otides (ODNs), significant protection was observed.
C57BL/6 mice (6 to 8 weeks old; Jackson Laboratories,
Bar Harbor, ME) were infected subcutaneously with 5  106
stationary-phase L. major substrain LV39 clone 5 (MRHO/
SU/59/P; wild type [WT]) or the lpg2 mutant (9). The
course of infection and parasite titers in the infected feet
were then assessed. As expected, C57BL/6 mice infected
with WT parasites developed small lesions that started to
resolve spontaneously around week 8. In contrast, and con-
sistent with our previous reports (9, 10), no lesions were
observed in lpg2 mutant-infected C57BL/6 mice (Fig. 1A).
The lack of disease in lpg2 mutant-infected mice was not
due to their destruction, as comparable numbers of parasites
could be reisolated from the footpads of WT or lpg2 mu-
tant-infected animals by the limiting dilution assay at 10
weeks postinfection (Fig. 1B).
We then compared the immune responses in C57BL/6
mice following infection with WT or lpg2 mutant parasites.
At various time points after infection (3 days, 4 weeks, and
10 weeks), single-cell suspensions from draining lymph
nodes (LNs) were cultured in the presence of leishmanial
freeze-thawed antigen (the equivalent of 107 parasites/ml),
and the supernatants were collected and assayed for IFN-
production. At 3 days postinfection, comparable levels of
IFN- were detected after in vitro restimulation of cells
from mice infected with WT and lpg2 parasites (Fig. 1C),
indicating that the ability of lpg2 mutants to induce an
early Th1 response in C57BL/6 mice was equivalent to that
of WT parasites. However, this response rapidly waned; the
levels of IFN- produced by cells from mice infected with
lpg2 parasites significantly decreased at 4 weeks and were
almost undetectable at 10 weeks postinfection. In contrast,
IFN- production by cells from WT-infected mice increased
over time (Fig. 1C). This lack of IFN- production by cells
from lpg2 mutant-infected mice was not due to a shift to a
Th2 cytokine response, as we also were unable to detect any
measurable production of IL-4 or IL-10 by cells from lpg2
mutant-infected mice (data not shown). Taken together,
these data indicate that the ability of lpg2 mutants to
continuously stimulate an effector T-cell response is dramat-
ically impaired.
To determine whether lpg2 parasites can confer protec-
tion in C57BL/6 mice, after 10 weeks of infection with lpg2
or WT parasites, these animals, or naı¨ve controls, were
challenged in their contralateral footpads with WT L. major
parasites. Parasite loads were then compared between naı¨ve
and infected animals 5 weeks after challenge. As shown in
Fig. 2A, WT-infected mice had significantly lower parasite
loads than naı¨ve (unvaccinated) animals, which harbored
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104 parasites in their lesions. Surprisingly—and unlike
BALB/c mice—C57BL/6 mice vaccinated with lpg2 para-
sites had lower parasite loads, but not significantly so, than
naı¨ve controls. Furthermore, C57BL/6 mice previously in-
fected with lpg2 parasites for 10 weeks mounted a very
weak DTH response, comparable to that exhibited by naı¨ve
animals, while healed WT mice exhibited a robust DTH
response typical of a classical anti-Leishmania immunity
(Fig. 2B).
The inability of lpg2 parasites to confer significant pro-
tection to C57BL/6 mice could be related to the minimal
immune response seen prior to challenge (Fig. 2C), al-
though in lpg2 mutant-infected BALB/c mice—which were
protected from challenge with WT parasites—a similarly
weak immune response was observed (10). Nevertheless, we
tested whether enhancing the immune response with adju-
vants would promote increased protective immunity. CpG
ODNs, potent inducers of a Th1 response, have been widely
used as effective adjuvants for diseases requiring Th1 im-
mune responses, such as leishmaniasis (5, 6, 12). We there-
fore asked whether coinjection of lpg2 parasites with CpG
ODNs would enhance the lpg2 mutant-induced protection.
C57BL/6 mice were immunized with lpg2 parasites in com-
bination with a single dose (50 g/mouse) of immunostimu-
latory CpG ODNs (sequence 1826 [5-TCC ATG ACG TTC
CTG ACG TT-3]) or non-CpG ODNs (sequence 1982 [5-
TCC AGG ACT TCT CTC AGG TT-3] used as a control)
(Coley Pharmaceutical Group, Inc., Wellesley, MA). When
challenged with WT parasites, lpg2 mutant- plus CpG
ODN-vaccinated mice showed a hundredfold reduction in
parasite burdens compared to those in naı¨ve unvaccinated
animals (Fig. 2A). Interestingly, the protective immunity
induced by inclusion of CpG ODNs with the lpg2 parasites
was not associated with a strong effector T-cell response at
the time of challenge. Thus, lpg2 mutant- plus CpG ODN-
vaccinated-mice did not mount a significantly stronger DTH
response than mice receiving lpg2 parasites alone (Fig.
2B). Moreover, lymph node cells taken from lpg2 mutant-
plus CpG ODN-vaccinated-mice prior to challenge did not
produce significantly more IFN- than lpg2 mutant-in-
fected mice (Fig. 2C). Taken together, these data indicate
that mice vaccinated with lpg2 parasites in combination
with a single dose of CpG ODNs are protected against WT
parasites in the absence of a strong immune response.
A striking feature of infection with lpg2 parasites in
BALB/c mice was the rapid waning of the effector immune
response, in spite of the long-term maintenance of protection
(10). We saw a similar pattern in C57BL/6 mice infected with
lpg2 parasites, even when CpG ODNs were included in the
vaccine. Thus, these results argue that the minimal immune
response seen in lpg2 mutant-infected C57BL/6 mice at 10
weeks of infection is not likely to be the reason that these
animals are not strongly protected. Studies are under way to
define the mechanism involved in the protective immunity as-
sociated with lpg2 parasites. However, whatever the mecha-
nism, it is clear from the data reported in this study and our
previous work using lpg2 parasites in BALB/c mice that the
presence of DTH and large numbers of IFN--producing T
cells prior to challenge are not required for protective immu-
nity. Additional studies with more-sensitive assays will be re-
quired to determine if any effector T cells are present prior to
challenge.
A substantial body of literature indicates that parasite
persistence is associated with optimal immunity to L. major
(3, 11, 13), which suggests that the best vaccine for leish-
FIG. 1. C57BL/6 mice infected with lpg2 mutants exhibit no pa-
thology but are unable to maintain a strong Th1 response. (A) Mice
were vaccinated subcutaneously in their footpads with 5  106 station-
ary-phase promastigotes of L. major LV39 (WT) or lpg2 parasites.
Lesion progression was monitored weekly. Results are expressed as
mean footpad thickness increases  standard errors of the means.
(B) Mice were sacrificed 10 weeks (Wks) after infection to assess
parasite burden. (C) Leishmania-specific recall responses by LN cell
suspensions from C57BL/6 mice infected for 3 days, 4 weeks, or 10
weeks with 5  106 WT or lpg2 L. major parasites. Data shown
represent the mean increases  standard deviations for three mice
per group.
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maniasis may require live, attenuated parasites. Spa¨th et al.
found that lpg2 parasites persist in BALB/c mice without
disease (9), and we reported that lpg2 mutant-infected
BALB/c mice are resistant to challenge with virulent L.
major (10). Here we show that while C57BL/6 mice infected
with lpg2 parasites alone are not protected against chal-
lenge with virulent L. major, mice vaccinated with CpG
ODNs as an adjuvant with lpg2 parasites, exhibited signif-
icant protection. Furthermore, mice receiving this live, at-
tenuated vaccine were resistant to rechallenge for at least 10
weeks after the immunization. These results are similar to
those obtained when mice were immunized with virulent
parasites in conjunction with CpG ODNs, but they have the
advantage of the use of an attenuated organism (4). Taken
together with our previous study of BALB/c mice (10), these
results indicate that attenuated parasites are able to induce
long-term immunity to leishmaniasis. However, the ability of
lpg2 parasites to provide protection in BALB/c mice (10),
but not in C57BL/6 mice, was a surprise, although we cannot
rule out the possibility that different doses of parasites, or
additional injections of the parasites, might give better pro-
tection. Nevertheless, while previous studies have demon-
strated that the presence of WT L. major parasites in
C57BL/6 mice is associated with immunity to reinfection (1,
2, 11), our data unexpectedly indicate that the presence of
persistent parasites alone is not sufficient to maintain pro-
tective immunity. Thus, future studies using lpg2 parasites
may help to identify the essential characteristics associated
with persistent infection that promote the maintenance of
protective immunity.
This work was supported by Public Health Service grant AI-059396
from the National Institute of Allergy and Infectious Disease.
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